BNP Paribas Financial Markets
ACTU

BNP Paribas Financial Markets’s Actuate Therapeutics ACTU Stock Holding History

BNP Paribas Financial Markets’s Portfolio ACTU Stock Details ACTU Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$6.83K Buy
2,492
+100
+4% +$414 ﹤0.01% 5281
2025
Q4 		$14.6K Buy
2,392
+832
+53% +$5.71K ﹤0.01% 5087
2025
Q3 		$10.4K Buy
1,560
+655
+72% +$4.75K ﹤0.01% 5002
2025
Q2 		$5.53K Buy
+905
New +$7.91K ﹤0.01% 4949

Other funds holding ACTU

BCM
BIOS Capital Management Fort Worth, Texas $52.9M AUM 30.51% 1-Year Est. Return
VC
Voss Capital Houston, Texas $1.88B AUM 1.03% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
CCM
Connective Capital Management Palo Alto, California $121M AUM 39.82% 1-Year Est. Return
PVM
Palogic Value Management Dallas, Texas $237M AUM 5.37% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
TCBWMS
Texas Capital Bank Wealth Management Services Dallas, Texas $1.68B AUM 21.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

BNP Paribas Financial Markets's ACTU Position: Q1 2026 in Review

BNP Paribas Financial Markets increased its Actuate Therapeutics (ACTU) stake by 4.2% in Q1 2026, buying an estimated $414 and bringing the position to 2,492 shares worth $6.83K. The position accounts for ﹤0.01% of the portfolio, ranked #5281.

BNP Paribas Financial Markets first reported a position in ACTU in Q2 2025 and has held it in 4 quarters since. The position peaked at $14.6K in Q4 2025. 61 funds tracked by Wall St. Rank hold ACTU as of Q1 2026.

  • BNP Paribas Financial Markets held 2,492 shares of Actuate Therapeutics worth $6.83K as of Q1 2026.
  • BNP Paribas Financial Markets bought 100 Actuate Therapeutics shares in Q1 2026, an estimated $414.
  • Actuate Therapeutics made up ﹤0.01% of BNP Paribas Financial Markets's portfolio in Q1 2026, its #5281 holding.
  • BNP Paribas Financial Markets first reported a position in Actuate Therapeutics in Q2 2025 and has held it in 4 quarters since.
  • BNP Paribas Financial Markets's Actuate Therapeutics position peaked at $14.6K in Q4 2025.
  • 61 funds tracked by Wall St. Rank held Actuate Therapeutics as of Q1 2026.

Based on BNP Paribas Financial Markets's 13F filing for Q1 2026, filed 12 May 2026.